RU2018103960A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018103960A3 RU2018103960A3 RU2018103960A RU2018103960A RU2018103960A3 RU 2018103960 A3 RU2018103960 A3 RU 2018103960A3 RU 2018103960 A RU2018103960 A RU 2018103960A RU 2018103960 A RU2018103960 A RU 2018103960A RU 2018103960 A3 RU2018103960 A3 RU 2018103960A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198518P | 2015-07-29 | 2015-07-29 | |
| US62/198,518 | 2015-07-29 | ||
| US201562205185P | 2015-08-14 | 2015-08-14 | |
| US62/205,185 | 2015-08-14 | ||
| PCT/US2016/044838 WO2017020001A2 (en) | 2015-07-29 | 2016-07-29 | Heavy chain only antibodies to ang-2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018103960A RU2018103960A (ru) | 2019-08-28 |
| RU2018103960A3 true RU2018103960A3 (OSRAM) | 2020-01-16 |
| RU2749674C2 RU2749674C2 (ru) | 2021-06-16 |
Family
ID=56610025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018103960A RU2749674C2 (ru) | 2015-07-29 | 2016-07-29 | Антитела против ang-2, содержащие только тяжелую цепь |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10266589B2 (OSRAM) |
| EP (2) | EP3792279A3 (OSRAM) |
| JP (1) | JP6916776B2 (OSRAM) |
| CN (1) | CN107849126B (OSRAM) |
| AU (2) | AU2016298398A1 (OSRAM) |
| BR (1) | BR112018001762A2 (OSRAM) |
| CA (1) | CA2992660A1 (OSRAM) |
| DK (1) | DK3328886T3 (OSRAM) |
| ES (1) | ES2828694T3 (OSRAM) |
| HU (1) | HUE051165T2 (OSRAM) |
| PL (1) | PL3328886T3 (OSRAM) |
| RU (1) | RU2749674C2 (OSRAM) |
| WO (1) | WO2017020001A2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| HUE051165T2 (hu) * | 2015-07-29 | 2021-03-01 | Allergan Inc | ANG-2 elleni, csak nehézláncot tartalmazó antitestek |
| WO2017030909A1 (en) * | 2015-08-14 | 2017-02-23 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
| US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
| WO2022098925A1 (en) * | 2020-11-04 | 2022-05-12 | Fate Therapeutics, Inc. | Engineered ipsc and immune effector cells for heterogenous tumor control |
| CN116003591B (zh) * | 2022-12-12 | 2023-09-19 | 三门峡市眼科医院 | Ang-2抗体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| CA2495621C (en) | 2002-09-18 | 2008-02-12 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| CA2580336C (en) | 2004-07-22 | 2016-07-19 | Roger Kingdon Craig | Vh heavy chain only antibodies, and vh heavy chain only dimer compounds and uses thereof |
| EP2457578B1 (en) * | 2004-09-28 | 2015-08-19 | Aprogen, Inc. | Chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in treating penile erectile dysfunction |
| KR101017301B1 (ko) * | 2004-12-21 | 2011-02-28 | 메드임뮨 리미티드 | 앤지오포이에틴-2에 대한 항체 및 그의 용도 |
| SG169348A1 (en) | 2006-01-25 | 2011-03-30 | Univ Erasmus Medical Ct | Generation of heavy-chain only antibodies in transgenic animals |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2746395C (en) * | 2008-12-10 | 2019-07-09 | Ablynx N.V. | Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis |
| GB0905023D0 (en) * | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| EA031182B1 (ru) * | 2012-03-30 | 2018-11-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Ang2-связывающие молекулы |
| CN104395339A (zh) * | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途 |
| MX361337B (es) | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| BR112015010722A2 (pt) * | 2012-11-09 | 2017-08-22 | Pfizer | Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
| US9902767B2 (en) * | 2013-07-29 | 2018-02-27 | Samsung Electronics Co., Ltd. | Method of blocking vascular leakage using an anti-ANG2 antibody |
| KR102146845B1 (ko) * | 2013-07-30 | 2020-08-21 | 삼성전자주식회사 | 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
| CA2963723A1 (en) * | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-pdgf-b antibodies and methods of use |
| HUE051165T2 (hu) * | 2015-07-29 | 2021-03-01 | Allergan Inc | ANG-2 elleni, csak nehézláncot tartalmazó antitestek |
| WO2017030909A1 (en) * | 2015-08-14 | 2017-02-23 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
-
2016
- 2016-07-29 HU HUE16748025A patent/HUE051165T2/hu unknown
- 2016-07-29 WO PCT/US2016/044838 patent/WO2017020001A2/en not_active Ceased
- 2016-07-29 JP JP2018504124A patent/JP6916776B2/ja not_active Expired - Fee Related
- 2016-07-29 ES ES16748025T patent/ES2828694T3/es active Active
- 2016-07-29 AU AU2016298398A patent/AU2016298398A1/en not_active Abandoned
- 2016-07-29 DK DK16748025.0T patent/DK3328886T3/da active
- 2016-07-29 RU RU2018103960A patent/RU2749674C2/ru active
- 2016-07-29 US US15/223,855 patent/US10266589B2/en active Active
- 2016-07-29 CN CN201680044324.2A patent/CN107849126B/zh not_active Expired - Fee Related
- 2016-07-29 EP EP20187139.9A patent/EP3792279A3/en not_active Withdrawn
- 2016-07-29 EP EP16748025.0A patent/EP3328886B1/en active Active
- 2016-07-29 CA CA2992660A patent/CA2992660A1/en active Pending
- 2016-07-29 PL PL16748025T patent/PL3328886T3/pl unknown
- 2016-07-29 BR BR112018001762A patent/BR112018001762A2/pt not_active IP Right Cessation
-
2019
- 2019-04-16 US US16/385,384 patent/US11046756B2/en not_active Expired - Fee Related
-
2021
- 2021-06-28 US US17/361,180 patent/US20210324064A1/en not_active Abandoned
-
2022
- 2022-10-26 AU AU2022259761A patent/AU2022259761A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3328886T3 (da) | 2020-11-02 |
| AU2016298398A1 (en) | 2018-02-08 |
| EP3792279A3 (en) | 2021-07-07 |
| US20210324064A1 (en) | 2021-10-21 |
| US20190248882A1 (en) | 2019-08-15 |
| BR112018001762A2 (pt) | 2018-09-18 |
| RU2018103960A (ru) | 2019-08-28 |
| ES2828694T3 (es) | 2021-05-27 |
| CN107849126B (zh) | 2022-04-08 |
| PL3328886T3 (pl) | 2021-02-08 |
| CA2992660A1 (en) | 2017-02-02 |
| WO2017020001A3 (en) | 2017-03-16 |
| US20170107279A1 (en) | 2017-04-20 |
| RU2749674C2 (ru) | 2021-06-16 |
| HUE051165T2 (hu) | 2021-03-01 |
| HK1253947A1 (en) | 2019-07-05 |
| WO2017020001A2 (en) | 2017-02-02 |
| US10266589B2 (en) | 2019-04-23 |
| AU2022259761A1 (en) | 2022-12-01 |
| JP2018527327A (ja) | 2018-09-20 |
| EP3328886B1 (en) | 2020-09-16 |
| EP3792279A2 (en) | 2021-03-17 |
| EP3328886A2 (en) | 2018-06-06 |
| CN107849126A (zh) | 2018-03-27 |
| US11046756B2 (en) | 2021-06-29 |
| JP6916776B2 (ja) | 2021-08-11 |